NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

• Published in: Breast cancer research : BCR Vol. 26; no. 1; p. 69
• Main Authors: Jacobs, Samuel A, Wang, Ying, Abraham, Jame, Feng, Huichen, Montero, Alberto J, Lipchik, Corey, Finnigan, Melanie, Jankowitz, Rachel C, Salkeni, Mohamad A, Maley, Sai K, Puhalla, Shannon L, Piette, Fanny, Quinn, Katie, Chang, Kyle, Nagy, Rebecca J, Allegra, Carmen J, Vehec, Kelly, Wolmark, Norman, Lucas, Peter C, Srinivasan, Ashok, Pogue-Geile, Katherine L
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22-04-2024; BioMed Central; BMC
• Subjects: Ado-Trastuzumab Emtansine - therapeutic use; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - genetics; Biopsy; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer therapies; Care and treatment; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Clinical trial; Clinical trials; Copy number; ctDNA HER2 amplification; ErbB-2 protein; Female; Genes; Humans; Medical research; Medicine, Experimental; Metastases; Metastasis; Metastatic breast cancer; Middle Aged; Mutation; Neoplasm Metastasis; Neratinib + t-DM1; Patients; Pertuzumab; Quinolines - administration & dosage; Quinolines - therapeutic use; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; RNA; Toxicity; Transcriptomes; Trastuzumab; Trastuzumab - administration & dosage; Trastuzumab - therapeutic use; Treatment Outcome; ctDNA HER2 amplification; Clinical trial; Metastatic breast cancer; Neratinib + t-DM1
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-024-01823-8

We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. This study extends these observations with in-depth analysis of molecular markers and mechanisms of resistance in additional patients.
Forty-nine HER2-positive patients (determined locally) who progressed on-treatment with trastuzumab + pertuzumab were enrolled in this phase Ib/II study. Mutations and HER2 amplifications were assessed in ctDNA before (C1D1) and on-treatment (C2D1) with the Guardant360 assay. Archived tissue (TP0) and study entry biopsies (TP1) were assayed for whole transcriptome, HER2 copy number, and mutations, with Ampli-Seq, and centrally for HER2 with CLIA assays. Patient responses were assessed with RECIST v1.1, and Molecular Response with the Guardant360 Response algorithm.
The ORR in phase II was 7/22 (32%), which included all patients who had at least one dose of study therapy. In phase I, the ORR was 12/19 (63%), which included only patients who were considered evaluable, having received their first scan at 6 weeks. Central confirmation of HER2-positivity was found in 83% (30/36) of the TP0 samples. HER2-amplified ctDNA was found at C1D1 in 48% (20/42) of samples. Patients with ctHER2-amp versus non-amplified HER2 ctDNA determined in C1D1 ctDNA had a longer median progression-free survival (PFS): 480 days versus 60 days (P = 0.015). Molecular Response scores were significantly associated with both PFS (HR 0.28, 0.09-0.90, P = 0.033) and best response (P = 0.037). All five of the patients with ctHER2-amp at C1D1 who had undetectable ctDNA after study therapy had an objective response. Patients whose ctHER2-amp decreased on-treatment had better outcomes than patients whose ctHER2-amp remained unchanged. HER2 RNA levels show a correlation to HER2 CLIA IHC status and were significantly higher in patients with clinically documented responses compared to patients with progressive disease (P = 0.03).
The following biomarkers were associated with better outcomes for patients treated with T-DM1 + neratinib: (1) ctHER2-amp (C1D1) or in TP1; (2) Molecular Response scores; (3) loss of detectable ctDNA; (4) RNA levels of HER2; and (5) on-treatment loss of detectable ctHER2-amp. HER2 transcriptional and IHC/FISH status identify HER2-low cases (IHC 1+ or IHC 2+ and FISH negative) in these heavily anti-HER2 treated patients. Due to the small number of patients and samples in this study, the associations we have shown are for hypothesis generation only and remain to be validated in future studies. Clinical Trials registration NCT02236000.